netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Palbociclib found 6 matches

Open monograph to display formulary status BNF Category
  Palbociclib  (Ibrance®) Malignant disease and immunosuppression - Breast cancer - 08.03.04.01
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
link in drug section MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
link in drug section MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
link in drug section NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (08.03.04.01)
link in drug section NICE TA836: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (08.03.04.01)


 

netFormulary